Impact Of Underlying Pulmonary Diseases On Treatment Outcomes In Early-Stage Non-Small Cell Lung Cancer Treated With Definitive Radiotherapy

Purpose: Current guidelines recommend definitive radiotherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). However, the impact of underlying pulmonary diseases on survival in those patients remains unclear. Methods: We retrospectively reviewed the medical re...

Full description

Saved in:
Bibliographic Details
Published in:International journal of chronic obstructive pulmonary disease 2019-10, p.2273
Main Authors: Kim, Hakyoung, Yoo, Hongseok, Pyo, Hongryull, Ahn, Yong Chan, Noh, Jae Myoung, Ju, Sang Gyu, Lee, Woojin, Park, Byoungsuk, Kim, Jin Man, Kang, Noeul, Shin, Sun Hye, Chung, Man Pyo, Shin, Sumin, Kim, Hye Seung, Park, Minsu, Park, Hye Yun
Format: Article
Language:English
Subjects:
Care and treatment
Chronic obstructive lung disease
Comparative analysis
Development and progression
Emphysema
Fibrosis
Lung cancer
Lung diseases
Medical centers
Medical research
Non-small cell lung cancer
Patient outcomes
Pirfenidone
Pulmonary fibrosis
Radiotherapy
Respiratory tract diseases
Small cell lung cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: Current guidelines recommend definitive radiotherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC). However, the impact of underlying pulmonary diseases on survival in those patients remains unclear. Methods: We retrospectively reviewed the medical records of 234 patients with stage I-II NSCLC treated with definitive radiotherapy alone at Samsung Medical Center between January 2010 and October 2017. We compared survival outcomes according to the presence of underlying pulmonary diseases, including chronic obstructive pulmonary disease (COPD), combined pulmonary fibrosis and emphysema (CPFE), and idiopathic pulmonary fibrosis (IPF). The control group in this study was stage I-II NSCLC patients who were non-COPD, non-CPFE, and non-IPF. Results: The median follow-up duration was 17 (range, 1-92) months. The median survival times of the control, COPD, CPFE, and IPF groups were 32, 49, 17, and 12 months, respectively (P
ISSN:1178-2005
DOI:10.2l47/COPD.S2l0759